Achieve Life Sciences (ACHV) Change in Account Payables (2012 - 2026)
Achieve Life Sciences' (ACHV) quarterly Change in Account Payables came in at -$53000.0 in Q1 2026, up 81.91% YoY from -$29135.1 in Q1 2025, and down 453.33% on a QoQ basis from $15000.0 in Q4 2025.
Achieve Life Sciences (ACHV) Change in Account Payables (2012 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 15 years of Change in Account Payables data on file, last reported at -$53000.0 in Q1 2026.
- Quarterly Change in Account Payables rose 81.91% year-over-year to -$53000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $248000.0 (down 80.69% YoY) and the FY2025 annual result came in at $8000.0, down 99.4% from the prior year.
- Change in Account Payables declined to -$53000.0 in Q1 2026, from $15000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.2 million in Q4 2022 to a low of -$702000.0 in Q2 2023.
- A 5-year average of $61411.8 and a median of -$20000.0 in 2023 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2023 — Change in Account Payables slumped 394.96% — and 2024, when it surged 4795.0%.
- Tracing ACHV's Change in Account Payables over 5 years: stood at $1.2 million in 2022, then tumbled by 101.63% to -$20000.0 in 2023, then surged by 4795.0% to $939000.0 in 2024, then tumbled by 98.4% to $15000.0 in 2025, then plunged by 453.33% to -$53000.0 in 2026.
- The last three Change in Account Payables figures came in at -$53000.0 (Q1 2026), $15000.0 (Q4 2025), and $725000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | -200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -200,000.00 |
| Jun 30, 2026 | -200,000.00 |
| Mar 31, 2026 | -53,000.00 |
| Mar 31, 2026 | -53,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2025 | 725,000.00 |
| Sep 30, 2025 | 725,000.00 |
| Jun 30, 2025 | -439,000.00 |
| Jun 30, 2025 | -439,000.00 |
| Mar 31, 2025 | -293,000.00 |
| Mar 31, 2025 | -293,000.00 |
| Dec 31, 2024 | 939,000.00 |
| Dec 31, 2024 | 939,000.00 |
| Sep 30, 2024 | 461,000.00 |
| Sep 30, 2024 | 461,000.00 |
| Jun 30, 2024 | 177,000.00 |
| Jun 30, 2024 | 177,000.00 |
| Mar 31, 2024 | -245,000.00 |
| Mar 31, 2024 | -245,000.00 |